In India the company plans to begin marketing the oral herpes device pursuant to the exclusive worldwide distribution rights it acquired from NeuroMed, as previously announced. The company expects to begin marketing the device through a wholly owned Indian subsidiary, via direct web based/internet marketing, retail, wholesale and through physicians and hospitals within the next 30 days.
While the company’s initial focus was on securing US FDA approval to distribute the company’s proprietary Biofield Diagnostic System for the early detection of breast cancer (the “BDS”) in the US., the company has reoriented and expanded its energies to focus on offering non-invasive and cost effective technologies, on an easily accessible basis, to the world’s largest population centers. The company anticipates achieving its goal by generating sales of the BDS in foreign markets and acquiring other non-invasive detection and prevention technologies. The company is currently focusing on distributing its product portfolio in China (including Hong Kong, Taiwan and Macau), India, the Philippines, Indonesia, Malaysia, Singapore, Vietnam, and other parts of Asia, Mexico, Latin America and Europe.
Shepard G. Bentley, the company’s chief executive officer, stated: “We are very pleased to be able to add a HPV diagnostic test for cervical cancer as well as ValioRx’s HyperGenomics™ and Nucleosomics™ cancer diagnostics products to our portfolio. When combining these products with those which we acquired pursuant to an exclusive worldwide distribution agreement with NeuroMed Devices, Inc. for the treatment of oral and genital herpes, with our own proprietary BDS, we are extremely well positioned to provide a broad range of non-invasive products and services.”
James MacKay, chairman of the The MacKay Holdings Limited and majority shareholder of Biofield added: “We anticipate sales of our portfolio of products in China over the near term through the new Chinese national healthcare joint venture, Worldwide Lifecare Limited. This joint venture, which is a partnership between the National Labor Union, China’s top Financial Institutions, and been funded with approximately US$350 million by the Chinese Government, is anticipated to open more than 500 medical clinic centers across China before 2012 and provide a variety of Biofield’s products and services in its clinics. The Company has reoriented its energies to focus on offering non-invasive and cost effective technologies to the public. Our mission and goal is to bring technologies to the people through our worldwide (i.e. China, India and Europe) network and to make it easily accessible. My private company, The MacKay Holdings Limited (MKG) strength is the network with key people and Governments in different countries. The objective is to utilize MKG to establish a worldwide channel for distributing Biofield’s technologies. MKG becomes the bridge between the east and the west, no more no less.”